Literature DB >> 2688863

Cocaine: pharmacokinetics and biotransformation in man.

T Inaba1.   

Abstract

Pharmacokinetic studies of cocaine have been carried out only in the last decade, although its local anesthetic action and addictive properties have been known for almost 100 years. Elimination half-lives of cocaine in man estimated from serial plasma concentration are relatively short and range from 0.5 to 1.1 h after i.v. and 0.9-1.5 h after administration by the nasal or oral route. The bioavailability after nasal inhalation is about 60%. The bicyclic structure of cocaine is characterized by functional groups including N-methyl, carboxyl methyl ester, and benzoyl ester, which are susceptible to biotransformation. Hydrolysis of the benzoyl group to ecgonine methyl ester is catalyzed by plasma cholinesterase and is thus under monogenic control. The hydrolytic cleavage of the other ester group, methyl ester, to benzoyl ecgonine occurs spontaneously at body temperature. In contrast, N-demethylation of cocaine mediated by microsomal cytochrome P-450 produces norcocaine and this metabolite was shown to be pharmacologically active, the action being similar to cocaine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2688863     DOI: 10.1139/y89-184

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  12 in total

1.  Modafinil influences the pharmacokinetics of intravenous cocaine in healthy cocaine-dependent volunteers.

Authors:  Jennifer L Donovan; C Lindsay DeVane; Robert J Malcolm; Jurij Mojsiak; C Nora Chiang; Ahmed Elkashef; Robin M Taylor
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Long-term reduction of cocaine self-administration in rats treated with adenoviral vector-delivered cocaine hydrolase: evidence for enzymatic activity.

Authors:  Natalie E Zlebnik; Stephen Brimijoin; Yang Gao; Amy T Saykao; Robin J Parks; Marilyn E Carroll
Journal:  Neuropsychopharmacology       Date:  2014-01-10       Impact factor: 7.853

3.  Revisiting a physiologically based pharmacokinetic model for cocaine with a forensic scope.

Authors:  María Elena Bravo-Gómez; Laura Nayeli Camacho-García; Luz Alejandra Castillo-Alanís; Miguel Ángel Mendoza-Meléndez; Alejandra Quijano-Mateos
Journal:  Toxicol Res (Camb)       Date:  2019-03-13       Impact factor: 3.524

Review 4.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

5.  Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats.

Authors:  R M Booze; A F Lehner; D R Wallace; M A Welch; C F Mactutus
Journal:  Neurotoxicol Teratol       Date:  1997 Jan-Feb       Impact factor: 3.763

6.  Relationship between the discriminative stimulus effects and plasma concentrations of intramuscular cocaine in rhesus monkeys.

Authors:  X Lamas; S S Negus; E Hall; N K Mello
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

Review 7.  Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs.

Authors:  Jan Booij; Paul Kemp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-30       Impact factor: 9.236

8.  Functional and dispositional tolerance develops during continuous cocaine exposure.

Authors:  E K Johansson; S M Tucker; H B Ginn; B R Martin; M D Aceto
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441

9.  Fluoxetine, but not sertraline or citalopram, potentiates the locomotor stimulant effect of cocaine: possible pharmacokinetic effects.

Authors:  Paul J Fletcher; Judy Sinyard; Mahnaz Salsali; Glen B Baker
Journal:  Psychopharmacology (Berl)       Date:  2004-01-22       Impact factor: 4.530

10.  Cocaine-induced rausch: overt behaviour and plasma concentrations in rhesus monkeys.

Authors:  J J Saady; E R Bowman; M D Aceto
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jan-Mar       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.